PacBio, a US biotech company, has partnered with Singapore's National Precision Medicine (NPM) programme to enhance the organisation's genome sequencing capabilities.
The duo will utilise PacBio's HiFi sequencing technology to offer insights into the genetic diversity of the Southeast Asian population, as well as looking into the disease epigenetics within Singapore's multi-ethnic population in its long-read sequencing flagship project.
The project aims to optimise the healthcare offerings in Singapore, while also improving patient outcomes.
PacBio's long-read sequencing — according to the company — can detect large structural variations in the genetic code, as well as DNA methylation.
“I am delighted that PRECISE has selected our Revio system for their extensive, flagship long-read sequencing project in Singapore,” said President and CEO of PacBio, Christian Henry. “PRECISE chose PacBio HiFi technology for its capacity to deliver complete and accurate genomes. This project exemplifies Revio’s unique ability to provide differentiated solutions for large-scale, multi-thousand-sample, whole genome sequencing projects.”
PacBio's collaboration with PRECISE aims drive scientific breakthroughs and enhnace clinical outcomes for the diverse population of Singapore.
The company will also invest in local expertise and a comprehensive data platform to encourge the project's success.
